Literature DB >> 11529912

Autoantibodies from patients with coeliac disease recognize distinct functional domains of the autoantigen tissue transglutaminase.

J Seissler1, U Wohlrab, C Wuensche, W A Scherbaum, B O Boehm.   

Abstract

The enzyme tissue transglutaminase (tTG) has been recently identified to represent a highly sensitive and specific target of autoantibodies in coeliac disease. To characterize autoantigenic epitopes, we generated novel tTG deletion mutants by polymerase chain reaction, produced radiolabelled fragments by in vitro transcription/translation, immunoprecipitated the mutants using sera from patients with coeliac disease, and related the binding data with putative structural and functional domains of human tTG. We show that tTG antibody positive sera display a heterogeneous autoantibody response covering distinct regions of the molecule. The N-terminal and C-terminal third of tTG, comprising amino acid (aa) 1-281 and aa 473-687, harbour the dominant epitopes (67.4% and 69.4% positive), whereas the catalytic region is of minor antigenicity (22.5% positive). Autoantibodies directed to one, two and three domains were observed in 36.7%, 28.6% and 22.4% of patients, respectively. Comparative analysis revealed the presence of strictly conformational epitopes which were dependent on the N-terminus (aa 1-12) or the intact beta-barrel domains in the C-terminus (aa 473-497, aa 649-687). In conclusion, we here demonstrate for the first time that the humoral autoimmunity is directed against distinct functional tTG domains. The spectrum of autoantibodies indicates that the native folded protein may be the target of autoantibodies.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11529912      PMCID: PMC1906132          DOI: 10.1046/j.1365-2249.2001.01584.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  30 in total

1.  The structural basis for the regulation of tissue transglutaminase by calcium ions.

Authors:  R Casadio; E Polverini; P Mariani; F Spinozzi; F Carsughi; A Fontana; P Polverino de Laureto; G Matteucci; C M Bergamini
Journal:  Eur J Biochem       Date:  1999-06

2.  In vivo antigen challenge in celiac disease identifies a single transglutaminase-modified peptide as the dominant A-gliadin T-cell epitope.

Authors:  R P Anderson; P Degano; A J Godkin; D P Jewell; A V Hill
Journal:  Nat Med       Date:  2000-03       Impact factor: 53.440

3.  Early development and spreading of autoantibodies to epitopes of IA-2 and their association with progression to type 1 diabetes.

Authors:  H E Naserke; A G Ziegler; V Lampasona; E Bonifacio
Journal:  J Immunol       Date:  1998-12-15       Impact factor: 5.422

4.  Identification of tissue transglutaminase as the autoantigen of celiac disease.

Authors:  W Dieterich; T Ehnis; M Bauer; P Donner; U Volta; E O Riecken; D Schuppan
Journal:  Nat Med       Date:  1997-07       Impact factor: 53.440

Review 5.  Coeliac disease.

Authors:  M Mäki; P Collin
Journal:  Lancet       Date:  1997-06-14       Impact factor: 79.321

6.  Antibodies to human recombinant tissue transglutaminase measured by radioligand assay: evidence for high diagnostic sensitivity for celiac disease.

Authors:  J Seissler; S Boms; U Wohlrab; N G Morgenthaler; T Mothes; B O Boehm; W A Scherbaum
Journal:  Horm Metab Res       Date:  1999-06       Impact factor: 2.936

7.  Epitope spreading and a varying but not disease-specific GAD65 antibody response in Type I diabetes. The Childhood Diabetes in Finland Study Group.

Authors:  P Söhnlein; M Müller; K Syren; U Hartmann; B O Böhm; H M Meinck; M Knip; H K Akerblom; W Richter
Journal:  Diabetologia       Date:  2000-02       Impact factor: 10.122

8.  Immune reactivity of diabetes-associated human monoclonal autoantibodies defines multiple epitopes and detects two domain boundaries in glutamate decarboxylase.

Authors:  K Syren; L Lindsay; B Stoehrer; K Jury; F Lühder; S Baekkeskov; W Richter
Journal:  J Immunol       Date:  1996-12-01       Impact factor: 5.422

9.  Comparison of tissue transglutaminase-specific antibody assays with established antibody measurements for coeliac disease.

Authors:  E Bazzigaluppi; V Lampasona; G Barera; A Venerando; C Bianchi; G Chiumello; E Bonifacio; E Bosi
Journal:  J Autoimmun       Date:  1999-02       Impact factor: 7.094

10.  Serum immunoglobulin A from patients with celiac disease inhibits human T84 intestinal crypt epithelial cell differentiation.

Authors:  T Halttunen; M Mäki
Journal:  Gastroenterology       Date:  1999-03       Impact factor: 22.682

View more
  13 in total

Review 1.  Anti-type 2 transglutaminase antibodies as modulators of type 2 transglutaminase functions: a possible pathological role in celiac disease.

Authors:  Stefania Martucciello; Gaetana Paolella; Carla Esposito; Marilena Lepretti; Ivana Caputo
Journal:  Cell Mol Life Sci       Date:  2018-08-22       Impact factor: 9.261

2.  A single conformational transglutaminase 2 epitope contributed by three domains is critical for celiac antibody binding and effects.

Authors:  Zsófia Simon-Vecsei; Róbert Király; Péter Bagossi; Boglárka Tóth; Ingrid Dahlbom; Sergio Caja; Éva Csosz; Katri Lindfors; Daniele Sblattero; Éva Nemes; Markku Mäki; László Fésüs; Ilma R Korponay-Szabó
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-22       Impact factor: 11.205

3.  Immunoglobulin G (IgG) anti-tissue transglutaminase antibodies used as markers for IgA-deficient celiac disease patients.

Authors:  Ingrid Dahlbom; Martin Olsson; Nahal Kazemi Forooz; Anders G Sjöholm; Lennart Truedsson; Tony Hansson
Journal:  Clin Diagn Lab Immunol       Date:  2005-02

4.  Autoantibodies of patients with coeliac disease are insufficient to block tissue transglutaminase activity.

Authors:  W Dieterich; D Trapp; B Esslinger; M Leidenberger; J Piper; E Hahn; D Schuppan
Journal:  Gut       Date:  2003-11       Impact factor: 23.059

5.  Development of an immunocapture method for measuring IgA antibodies to tissue transglutaminase in the sera of patients with coeliac disease.

Authors:  S El Alaoui; C Gresti
Journal:  Clin Exp Immunol       Date:  2006-04       Impact factor: 4.330

6.  Reduction of tissue transglutaminase autoantibody levels by gluten-free diet is associated with changes in subsets of peripheral blood lymphocytes in children with newly diagnosed coeliac disease.

Authors:  D Agardh; K Lynch; C Brundin; S-A Ivarsson; A Lernmark; C M Cilio
Journal:  Clin Exp Immunol       Date:  2006-04       Impact factor: 4.330

Review 7.  Transglutaminases: nature's biological glues.

Authors:  Martin Griffin; Rita Casadio; Carlo M Bergamini
Journal:  Biochem J       Date:  2002-12-01       Impact factor: 3.857

Review 8.  The adaptive immune response in celiac disease.

Authors:  Shuo-Wang Qiao; Rasmus Iversen; Melinda Ráki; Ludvig M Sollid
Journal:  Semin Immunopathol       Date:  2012-04-26       Impact factor: 9.623

9.  In celiac disease, a subset of autoantibodies against transglutaminase binds toll-like receptor 4 and induces activation of monocytes.

Authors:  Giovanna Zanoni; Riccardo Navone; Claudio Lunardi; Giuseppe Tridente; Caterina Bason; Simona Sivori; Ruggero Beri; Marzia Dolcino; Enrico Valletta; Roberto Corrocher; Antonio Puccetti
Journal:  PLoS Med       Date:  2006-09       Impact factor: 11.069

10.  Transglutaminase 2-specific autoantibodies in celiac disease target clustered, N-terminal epitopes not displayed on the surface of cells.

Authors:  Rasmus Iversen; Roberto Di Niro; Jorunn Stamnaes; Knut E A Lundin; Patrick C Wilson; Ludvig M Sollid
Journal:  J Immunol       Date:  2013-05-20       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.